Search for: rheumatoid arthritis methotrexate autoimmune disease biomarker gene expression GWAS HLA genes non-HLA genes
| ID | PMID | Title | PublicationDate | abstract |
|---|---|---|---|---|
| 1837388 | [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment wit | 1991 Oct | Bucillamine is a useful medication for treatment of rheumatoid arthritis (RA) but some patients develop side effects from it. Here, we report a patient with RA developing a pemphigus-like skin lesion during treatment with bucillamine. A 55 year old woman with RA (stage III, class II) had been treated with bucillamine in our hospital since September 1988. Her symptoms of RA had gradually improved after administration of bucillamine but the generalized skin rash with itching developed in June 1989. Skin biopsy revealed spongiosis, the infiltration of lymphocytes in the epidermis and inter-cellular deposition of IgG. These findings were consistent with the histological change of pemphigus. Since symptoms of the skin disappeared two months later after the discontinuation of bucillamine. We considered that her pemphigus-like lesion was induced by this drug. D-penicillamine is one of the drugs which induce pemphigus. Though the mechanisms of this side effect have not been clear, it is thought that autoantibody induced by D-penicillamine could be one of the cause of pemphigus. Because the chemical structure of bucillamine is similar to that of D-penicillamine, the autoimmune mechanisms may also play a role in the onset of the pemphigus-like lesion in this case. | |
| 2810255 | Limited proliferative response to type II collagen in rheumatoid arthritis. | 1989 Oct | In order to define the potential importance of type II collagen in the activation of rheumatoid arthritis (RA) synovial fluid (SF) lymphocytes, we examined the proliferative response of matched peripheral blood and SF lymphocytes to type II collagen. The mean proliferative response to the collagen was somewhat greater (p less than 0.05) with SF, compared to peripheral blood lymphocytes. However, the magnitude of this response was relatively weak as determined by stimulation indices, and it did not approach that observed with peripheral blood lymphocytes in response to tetanus toxoid. Sixty-seven percent of peripheral bloods and 50% of SF demonstrated positive responses to the control antigen, tetanus toxoid. In contrast, only 6 and 28%, respectively, were positive in response to type II collagen. The addition of exogenous interleukin 2 augmented responses to the tetanus toxoid, however, no such enhancement with type II collagen was noted in our patients. Our collagen was arthritogenic in experimental animals. These observations do not support the existence of T cell specificity toward type II collagen as a common mechanism for the expansion of synovial lymphocytes in RA. | |
| 2129757 | Interleukin-2 inhibitor in rheumatoid arthritis synovial fluid does not inhibit mononuclea | 1990 | Synovial fluid (SF) from rheumatoid arthritis (RA) patients were tested for their ability to inhibit the proliferative responses of normal peripheral blood mononuclear cells (PBM) to mitogens and interleukin-2 (IL-2). SF significantly inhibited the responses to concanavalin A (CON A) and phytohaemagglutinin (PHA), but significantly enhanced the responses to IL-2. Similarly, SF mononuclear cells (SFM) were hyporesponsive to CON A and PHA compared with autologous PBM, but hyper-responsive to IL-2. It is concluded that an IL-2 inhibitor in RA SF is unlikely to be the cause of SFM hyporesponsiveness to mitogens. | |
| 2585408 | Comparing the short and long versions of the Arthritis Impact Measurement Scales. | 1989 Aug | Evidence is presented for the utilization of a shortened version of the Arthritis Impact Measurement Scales. The results confirmed that the shortened versions retained adequate internal consistencies, test-retest reliabilities, and both concurrent and predictive validities over a 2 year period which were similar to the original longer versions. | |
| 2829929 | Effect of synthetic calcium pyrophosphate and hydroxyapatite crystals on the interaction o | 1987 Dec | Synthetic calcium pyrophosphate dihydrate crystals and, to a lesser extent, synthetic hydroxyapatite crystals increased the amount of interleukin-1/mononuclear cell factor released by human blood monocytes, as measured by collagenase and prostaglandin E2 production by rabbit chondrocytes, human dermal fibroblasts, and adherent rheumatoid synovial cells. The same crystals also directly induced collagenase and prostaglandin E2 secretion by rabbit chondrocytes, and potentiated the action of interleukin-1/mononuclear cell factor on chondrocytes. These mechanisms may be important in the pathogenesis of the destructive arthropathies associated with these crystals. | |
| 2836309 | Effect of gold thiomalate on cell proliferation and collagen synthesis of synovial cells i | 1987 Oct | Human synovial cells from cases of rheumatoid and osteoarthritis were cultured and at their 3-5 passages, were treated with gold thiomalate. At early-log phase gold thiomalate arrested the proliferation of cells. However, at confluent state shere was a slight proliferation of synovial cells. This was followed by an increase in prolyl hydroxylase, collagen and protein synthesis, indicating that gold salts directly stimulate the synovial cells. | |
| 2121924 | Elevated soluble CD8 in the synovial fluid from patients with rheumatoid arthritis. | 1990 | Suppressor/cytotoxic T cells express the surface marker CD8, which can be measured in a soluble form in culture supernatants of activated human lymphocytes. Using a sandwich immunoassay, we assessed the levels of soluble CD8 (sCD8) in serum from patients with rheumatoid arthritis (RA; n = 82), patients with degenerative joint disease (DJD; n = 40), and healthy controls. There were no differences in serum sCD8 levels among these groups. In contrast, the levels of soluble CD8 in the synovial fluid (SF) from patients with RA (n = 53) were significantly increased compared with the levels in 23 samples from patients with DJD (821 +/- 110 U/ml versus 213 +/- 13 U/ml, p less than 0.001). Synovial fluid sCD8 levels in the RA group were strikingly elevated, to a maximum value of 5,026 U/ml. In the majority of RA SF specimens (39 of 53), the values were significantly higher in the SF than the serum. Although the RA group had higher values of sCD8, such values were not significantly correlated with measured laboratory or clinical parameters. Current clinical and laboratory methods of evaluating patients may not be adequate in dealing with the complexity and heterogeneity of RA. Soluble CD8 values may be useful in further grouping patients with this disease. | |
| 3781666 | Removal of denatured proteins with artificial reticulo-endothelial system (ARES). | 1986 Sep | Basic research has revealed that hydrophobic residues increased on the molecular surface of the denatured IgG and that the denatured proteins in the plasma can be removed by several sorbents of different amino acids bonded from polyvinylalcohol hydroxide residue with a covalent bond. Thus, an artificial reticulo-endothelial system was developed to supplement the human reticulo-endothelial system (RES) by removing denatured proteins from the patient's plasma. Clinically, angiitis and Raynaud's phenomenon associated with collagen disease such as systemic lupus erythematosus were remarkably reduced following a series of ARES treatments. The proteins adsorbed on the ARES were analyzed by two-dimensional electrophoresis. Virtually no albumin was detected, and IgG (constant isoelectric point), IgM, IgA, IgA dimer, C3, C4, fibrinogen and other unidentified spots were found in the elute from the ARES column. | |
| 2972426 | Deficient interleukin 2 production in rheumatoid arthritis: association with active diseas | 1988 Aug | Interleukin 2 (IL-2) production and proliferative responses of peripheral blood mononuclear cells (PBMC) stimulated with three concentrations of PHA were measured in 75 patients with rheumatoid arthritis (RA) and 25 normal controls. All patients were on a standard therapeutic regime, and were assessed for disease activity by clinical and laboratory criteria. Rheumatoid cells showed significantly lower IL-2 production and proliferation than normal PBMC at all PHA doses. These differences were not attributable to different kinetics. Within the rheumatoid population, both IL-2 levels and proliferation were lower in patients with active disease than those with inactive RA. Patients with extra-articular disease showed the most pronounced defects. Proliferative responses showed an inverse correlation with clinical indices of disease activity but not with measures of the acute phase response. Rheumatoid patients had higher proportions of CD4+, TFR+ and Tac+ lymphocytes than controls. Both proliferative responses and IL2- levels showed a positive relationship with the proportion of CD4+ cells, and an inverse relationship with Tac+ lymphocytes. Monocyte depletion and partial reconstitution resulted in an increase of both proliferation and IL-2 production, which was more marked in RA patients, suggesting that depressed IL-2 production may relate in part to monocyte effects. However, this cannot completely explain the magnitude of the defects observed, because normal monocytes did not increase the responses of rheumatoid lymphocytes, neither did rheumatoid monocytes suppress the responses of normal lymphocytes. | |
| 2323235 | Intrathoracic lymphadenopathy. A rare manifestation of rheumatoid pulmonary disease. | 1990 Apr | This is the first antemortem report of a patient with long-standing RA and interstitial lung disease who developed reactive mediastinal adenopathy coincident with increases in the activity of his interstitial process. Mediastinal adenopathy was discovered by means of CT of the chest as part of an evaluation of interstitial lung disease. The increasing use of better imaging techniques for this purpose will undoubtedly reveal more patients with this finding. Mediastinal lymphadenopathy complicating rheumatoid lung is clinically relevant; speculation is provided regarding the mechanism of the lymph node enlargement in this setting. | |
| 3435570 | Evidence for local synthesis of antibodies to denatured collagen in the synovium in rheuma | 1987 Dec | Synovial fluid samples from 36 patients with rheumatoid arthritis (RA) and 31 patients with other articular diseases (OAD) were examined for the presence of antibodies to denatured or native human type II collagen. Levels of IgG antibodies to denatured or native human type II collagen, rheumatoid factor, immunoglobulins, and total proteins were assessed in paired samples of serum and synovial fluid from 21 patients with RA and from 14 patients with OAD. Solid-phase radioimmunoassay showed that levels of antibodies to denatured collagen in synovial fluid were significantly higher in RA patients than in OAD patients (median 3,270, range 44-16,816 versus median 919, range 119-5,814; P less than 0.001). These antibody levels were higher in synovial fluid than in the serum of RA patients, but not in patients with OAD. Paired serum and synovial fluid samples showed no correlation between the level of antibodies to denatured collagen and levels of either IgG, IgA, IgM, or rheumatoid factor. Synovial fluid antibodies to native collagen were higher in RA patients. Antibodies to collagen may be synthesized preferentially in synovial tissues and, hence, participate in the perpetuation of RA. | |
| 2487701 | Treatment of rheumatoid arthritis. | 1989 Sep | The management of the rheumatoid patient involves the considered use of pharmacologic agents as therapies to induce symptomatic relief and to reduce disease activity. Aspirin and nonsteroidal antiinflammatory drugs are used initially to lessen the degree of pain and swelling associated with the inflammatory disease process. The aggressive institution of second-line therapy, previously known as disease-modifying antiinflammatory rheumatic drugs, is advocated to modify the disease course itself. These second-line treatments include antimalarials, gold salts, methotrexate, d-penicillamine, and azathioprine. Randomized placebo controlled trials have demonstrated the efficacy of these compounds in this illness. Improvement in standard parameters of disease activity (number of painful and swollen joints, duration of morning stiffness, erythrocyte sedimentation rate) can be related to the therapeutic value of second-line agents. Whether they modify radiographic progression is under rigorous study. Newer therapies under research investigation include sulfasalazine, cyclosporin A, and combination therapy. | |
| 3238355 | Evolution of the rheumatoid factor over time. | 1988 | With purpose to verify the epidemiological value of the Rheumatoid Factor's variations over time, we studied: 421 RA at first hospitalization (from 1976 to 1985; Group A); 348 consecutive RA with follow-up at 0, 6, 12, 24, and 48 months (Group B); 750 subjects, chosen at random from a healthy population, before and after 48 months (Group C). Five agglutination tests were used: three latex tests with human (2) and rabbit (1) IgGs; one red cells test on slide, and one in tube. The results were: uneven variations in positive results in all tests (Group A); the maximum confirmation of the basic profile are provide in short-term follow-up; in subsequent follow-ups, with the exclusion of the case of all the negative tests, the remaining profiles have a decreasing confirmation rate (Group B); the positive frequency is different in all the tests; this trend is sustained at follow-up (4 years later) in spite of the overall increase of positive results (Group C). Serum-positive RA, according to all or many tests, tend to reduce the number of positive results; healthy subjects (with few positive tests) tend to increase the number of positive results over time. RA with all the negative tests have a reasonably constant profile. | |
| 2163098 | Absence of circulating antineutrophil cytoplasm antibodies (ANCA) in severe vasculitis ass | 1990 | Sixteen patients with classical rheumatoid arthritis (RA) complicated by severe vasculitis were studied and compared with a matched control group of 17 RA patients without vasculitis. A control group of 24 patients with unrelated disease was also included. Neither antineutrophil cytoplasmic antibodies (C-ANCA) nor anti-myeloperoxidase (anti-MPO) were found. Granulocyte specific antinuclear antibodies ("GS-ANA") were found in a higher frequency in the vasculitis group (75%) than in the RA control group (41%), but the difference was not statistically significant. No patient in the control group without RA had "GS-ANA". | |
| 2657047 | Rheumatoid T lymphocyte MHC class II expression: in vitro stimulation produces normal MHC | 1989 Mar | MHC Class II mediated immune responses, such as tuberculin PPD, are often subnormal in rheumatoid arthritis (RA). We investigated peripheral blood T lymphocyte proliferation and Class II expression after stimulation with phytohemagglutinin, OKT3 and tuberculin PPD, using double label immunofluorescence and flow cytometry. No difference was found in the percentage of Class II positive T lymphocytes or intensity of fluorescence of Class II between matched controls and patients with RA. A disparity between Class II expression and proliferation was noted, particularly in the 50% of patients with RA with poor proliferation to PPD, who showed normal Class II expression, indicating that these 2 functions are under separate control. | |
| 3118019 | Antibodies to ribosomal ribonucleoprotein. Prevalence in systemic rheumatic diseases and p | 1987 Aug | The prevalence of antibodies to ribosomal ribonucleoproteins (rRNP) was studied in patients with rheumatic diseases. Seven patients had precipitating antibodies against rRNP, 6 had systemic lupus erythematosus, one had primary Sjögren's syndrome. Anti-rRNP was not present in mixed connective tissue disease, rheumatoid arthritis, progressive systemic sclerosis, CREST, primary Raynaud's or normal control sera. A partial immunological identity precipitin line was present between (U1) nRNP and rRNP, but these were distinct in physicochemical properties. Western blot analysis of ribosomal extract using anti-rRNP IgG revealed 2 polypeptides called rA and rB which appear to be the important antigenic determinants. | |
| 2279836 | Changes in walking ability after knee replacement. | 1990 | Walking ability has been assessed in 20 patients before and after knee replacement. In 8, who had severe osteoarthritis, a bicompartmental ICLH (Imperial College-London Hospital) prosthesis was used; in 12, with moderate arthritis, the medial side of the joint was replaced by a unicompartmental Brigham prosthesis. Knee function was assessed with the British Orthopaedic Association assessment chart, and walking capacity by the oxygen cost of level walking. Before operation, the function was the same in both groups, but patients with moderate osteoarthritis could walk faster with a lower energy cost than those with severe osteoarthritis. One year after operation, all the patients had improved clinically, alignment had been corrected, and the knees were stable with a satisfactory range of movement. Walking speed was improved; pain and perceived exertion were reduced. The oxygen cost of walking was decreased in patients with a unicompartmental arthroplasty, but not in patients with a total replacement. An uneconomic walking pattern, acquired before operation in those with severe osteoarthritis, was considered to be the reason why walking efficiency was not improved. The walking ability in patients with moderate osteoarthritis recovered to almost normal after unicompartmental replacement. | |
| 2799349 | [Severe acute pneumopathy following low-dose methotrexate therapy in chronic polyarthritis | 1989 Oct 14 | A 70-year-old patient with a history of rheumatoid arthritis was hospitalized for severe acute pneumonitis after 36 weeks of treatment with low-dose methotrexate (7.5 mg/week). High dose corticotherapy and assisted ventilation were necessary to obtain a clinical response. Medical history, clinical signs, laboratory findings. X-ray films of the chest and special investigations suggest the diagnosis of acute low-dose methotrexate pneumonitis. | |
| 3409643 | Sunbed-induced melanoma in a rheumatoid patient. | 1988 Mar | The development in a rheumatoid patient of a cutaneous malignant melanoma following repeated exposure to UV-A Radiation from a sunbed for its supposed therapeutic effect, is described. A causal-effect relationship is proposed and the potential risks to other arthritic patients and in particular those with pigmented skin lesions, is highlighted. | |
| 1874437 | [Genetic determination of rheumatoid arthritis. Distribution of certain Mendelian markers | 1991 Feb | The study on the nature of distribution of certain mendelian markers aimed at specifying their role in determination of rheumatoid arthritis disease was carried out, based on the material from the Family Data Bank of the Department of Epidemiology and Genetics of the rheumatic diseases in this institute comprising data on 200 families of patients with definite rheumatoid arthritis (RA). Antigens of HLA-system (the loci A, B, DR), ABO blood groups, Rh, MN and P, phenotypes of acid erythrocyte phosphatase and the types of haptoglobin were studied. Based on the data from this and the previous studies, it is established that the steadiest deviations of the RA patients groups from the general population concerned the frequency of HLA A11, B12, B27 and DR4, blood group P and phenotypes of the acid erythrocyte phosphatase. When using additional controls--a group of healthy mothers of women-probands from the families with the type of marriage "healthy x healthy", and analysing some pair combinations of the HLA system antigens, it was demonstrated that the most clearly their role in formation of the disease display the antigens DR4, and in their absence--DR3, and B12, whereas accumulation of A11 and B27 depended on the presence of other antigens of HLA loci--A and B. Taken together, these data may imply that genetic markers under study serve, when in certain combinations, as "modifiers" of the major gene, or, in a general case, of major genes of multifactorial disease affecting its appearance and clinical manifestations. |